NT-proBNP en pratique « De la biologie à la clinique »

Depuis l’introduction du dosage en routine des peptides natriuretiques, leurs applications cliniques se sont multipliees. Un nombre important de travaux ont defini les caracteristiques analytiques et l’interet clinique du dosage du NT-proBNP. Originellement limite a l’aide au diagnostic de l’insuffisance cardiaque aigue aux urgences, ce dosage a vu ses applications considerablement augmentees. Cette revue de la litterature presente un « etat de l’art » de ce marqueur, en detaillant les connaissances physiologiques recemment acquises et les applications cliniques reconnues ou en cours d’investigation du NT-proBNP.

[1]  G. Hillis,et al.  N-terminal pro B-type natriuretic peptide is an independent predictor of postoperative myocardial injury in patients undergoing major vascular surgery. , 2008, Journal of vascular surgery.

[2]  A. Jaffe,et al.  Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. , 2008, Clinical chemistry.

[3]  A. Bayés‐Genís,et al.  Understanding amino-terminal pro-B-type natriuretic peptide in obesity. , 2008, The American journal of cardiology.

[4]  J. Januzzi,et al.  Biology of the natriuretic peptides. , 2008, The American journal of cardiology.

[5]  J. Horáček,et al.  Assessment of anthracycline-induced cardiotoxicity with biochemical markers. , 2007, Experimental oncology.

[6]  N. Ziras,et al.  ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy. , 2007, International journal of cardiology.

[7]  P. Hildebrandt,et al.  Effects of body mass index and age on N-terminal pro brain natriuretic peptide are associated with glomerular filtration rate in chronic heart failure patients. , 2007, Clinical chemistry.

[8]  T. Walther,et al.  Successive Action of Meprin A and Neprilysin Catabolizes B-Type Natriuretic Peptide , 2007, Circulation research.

[9]  A. Bayés‐Genís,et al.  Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure. , 2007, International journal of cardiology.

[10]  J. Januzzi,et al.  N-Terminal Pro–B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart Failure: Primary Results of the Canadian Prospective Randomized Multicenter IMPROVE-CHF Study , 2007, Circulation.

[11]  P. Twomey,et al.  Using the single-compartment ratio model to calculate half-life, NT-proBNP as an example. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[12]  Faquan Liang,et al.  Evidence for functional heterogeneity of circulating B-type natriuretic peptide. , 2007, Journal of the American College of Cardiology.

[13]  Y. Pinto,et al.  Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. , 2007, Archives of internal medicine.

[14]  K. Bibbins-Domingo,et al.  N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. , 2007, JAMA.

[15]  Alan H B Wu,et al.  Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. , 2006, American heart journal.

[16]  Y. Pinto,et al.  Amino-terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction? , 2006, Journal of the American College of Cardiology.

[17]  G. Gazelle,et al.  Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. , 2006, The American journal of cardiology.

[18]  Y. Pinto,et al.  Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. , 2006, The American journal of cardiology.

[19]  C. Frampton,et al.  NTproBNP‐guided drug treatment for chronic heart failure: design and methods in the “BATTLESCARRED” trial , 2006, European journal of heart failure.

[20]  Jeroen J. Bax,et al.  Association of plasma N-terminal pro-B-type natriuretic peptide with postoperative cardiac events in patients undergoing surgery for abdominal aortic aneurysm or leg bypass. , 2006, The American journal of cardiology.

[21]  Antoni Bayes-Genis,et al.  NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. , 2006, European heart journal.

[22]  D. Lloyd‐Jones,et al.  Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. , 2006, Journal of the American College of Cardiology.

[23]  J. Rehfeld,et al.  BNP and N‐terminal proBNP are both extracted in the normal kidney , 2006, European journal of clinical investigation.

[24]  Y. Claessens,et al.  Influence of renal function on N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients admitted for dyspnoea in the Emergency Department: comparison with brain natriuretic peptide (BNP). , 2005, Clinica chimica acta; international journal of clinical chemistry.

[25]  N. Secher,et al.  Kidneys extract BNP and NT-proBNP in healthy young men. , 2005, Journal of applied physiology.

[26]  M. Olschewski,et al.  N-Terminal Pro-Brain Natriuretic Peptide or Troponin Testing Followed by Echocardiography for Risk Stratification of Acute Pulmonary Embolism , 2005, Circulation.

[27]  G. Martinelli,et al.  N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? , 2005, Clinical chemistry.

[28]  H. Yeh,et al.  Preoperative plasma N‐terminal pro‐brain natriuretic peptide as a marker of cardiac risk in patients undergoing elective non‐cardiac surgery , 2005, The British journal of surgery.

[29]  J. Paul,et al.  [Evaluation of the analytical performance characteristics of NT-proBNP immunoassay on dimension RxL-HM (Dade Behring)]. , 2005, Annales de biologie clinique.

[30]  R. Christenson,et al.  N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  Claudio Passino,et al.  Comparison of a fully automated immunoassay with a point-of-care testing method for B-type natriuretic peptide. , 2005, Clinical chemistry.

[32]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[33]  C. Hall.  NT-ProBNP: the mechanism behind the marker. , 2005, Journal of cardiac failure.

[34]  A. Loundou,et al.  NH2 terminal pro–brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients* , 2005, Critical care medicine.

[35]  C. Camargo,et al.  The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. , 2005, The American journal of cardiology.

[36]  G. Lefèvre,et al.  Dosage du BNP et du NT-proBNP : influence de l'étape préanalytique , 2005 .

[37]  Karen A. Hartman,et al.  Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure. , 2005, Clinical chemistry.

[38]  W. Roberts,et al.  Performance characteristics of four automated natriuretic peptide assays. , 2005, American journal of clinical pathology.

[39]  A. Jaffe,et al.  Quality specifications for B-type natriuretic peptide assays. , 2005, Clinical chemistry.

[40]  M. Emdin,et al.  Analytical performance and diagnostic accuracy of immunometric assays for the measurement of plasma B-type natriuretic peptide (BNP) and N-terminal proBNP. , 2005, Clinical chemistry.

[41]  D. J. Veldhuisen,et al.  Influence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/NT‐ANP and BNP/NT‐proBNP , 2005, European journal of heart failure.

[42]  J. Rehfeld,et al.  Acute myocardial hypoxia increases BNP gene expression , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  J. Goetze.  Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. , 2004, Clinical chemistry.

[44]  O. Vuolteenaho,et al.  Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. , 2004, Clinical chemistry.

[45]  G. Baxter,et al.  Acute actions of natriuretic peptides in coronary vasculature and ischaemic myocardium. , 2004, Current pharmaceutical design.

[46]  E. Frohlich,et al.  Obesity and suppressed B-type natriuretic peptide levels in heart failure. , 2004, Journal of the American College of Cardiology.

[47]  B. Hesse,et al.  Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction , 2004, European journal of heart failure.

[48]  M. Vogeser,et al.  Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[49]  J. Parner,et al.  N‐terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF) , 2004, European journal of heart failure.

[50]  M. Galvani,et al.  Natriuretic peptides for risk stratification of patients with acute coronary syndromes , 2004, European journal of heart failure.

[51]  Andrew K. Smith,et al.  Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure , 2004, European journal of heart failure.

[52]  T. Mueller,et al.  Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[53]  P. Casán,et al.  N‐terminal probrain natriuretic peptide (NT‐proBNP) in the emergency diagnosis and in‐hospital monitoring of patients with dyspnoea and ventricular dysfunction , 2004, European journal of heart failure.

[54]  P O Collinson,et al.  Analytical performance of the N terminal pro B type natriuretic peptide (NT‐proBNP) assay on the Elecsys™ 1010 and 2010 analysers , 2004, European journal of heart failure.

[55]  T. McDonagh,et al.  NT‐proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies , 2004 .

[56]  P. Bettencourt.  NT‐proBNP and BNP: biomarkers for heart failure management , 2004, European journal of heart failure.

[57]  C. Hall.  Essential biochemistry and physiology of (NT‐pro)BNP , 2004, European journal of heart failure.

[58]  M. Emdin,et al.  Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natr , 2004, Clinical chemistry and laboratory medicine.

[59]  D. Levy,et al.  Impact of Obesity on Plasma Natriuretic Peptide Levels , 2004, Circulation.

[60]  J. Cohn,et al.  The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. , 2004, European heart journal.

[61]  K. Lenz,et al.  Time course of B-type natriuretic peptide (BNP) and N-terminal proBNP changes in patients with decompensated heart failure. , 2004, Clinical chemistry.

[62]  N. Klitgaard,et al.  N‐terminal pro‐brain natriuretic peptide for discriminating between cardiac and non‐cardiac dyspnoea , 2004, European journal of heart failure.

[63]  F. van Lente,et al.  Plasma B-Type Natriuretic Peptide Levels in Ambulatory Patients With Established Chronic Symptomatic Systolic Heart Failure , 2003, Circulation.

[64]  A. Wu,et al.  Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[65]  T. McDonagh,et al.  N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. , 2003, European heart journal.

[66]  I. Squire,et al.  Pre‐discharge, but not admission, levels of NT‐proBNP predict adverse prognosis following acute LVF , 2003, European journal of heart failure.

[67]  R. Califf,et al.  N‐Terminal Pro‐Brain Natriuretic Peptide and Other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients With Unstable Coronary Artery Disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)‐IV Substudy , 2003, Circulation.

[68]  J. McMurray,et al.  N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure , 2003, Heart.

[69]  P. Hildebrandt,et al.  Value of N-Terminal proBNP in the Diagnosis of Left Ventricular Systolic Dysfunction in Primary Care Patients Referred for Echocardiography , 2003, Heart Drug.

[70]  J. Hollander,et al.  B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[71]  O. Nyvad,et al.  Abnormal rhythmic oscillations of atrial natriuretic peptide and brain natriuretic peptide in heart failure. , 2003, Clinical science.

[72]  C. Zanker,et al.  Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. , 2002, Journal of the American College of Cardiology.

[73]  C. Hengstenberg,et al.  N-Terminal Pro-Brain Natriuretic Peptide After Myocardial Infarction: A Marker Of Cardio-Renal Function , 2002, Hypertension.

[74]  M. Vogeser,et al.  Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.

[75]  K. Bailey,et al.  Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. , 2001, Mayo Clinic proceedings.

[76]  K. Swedberg,et al.  Guidelines for the diagnosis and treatment of chronic heart failure. , 2001, European heart journal.

[77]  E. Hartter,et al.  Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. , 2001, Journal of the American College of Cardiology.

[78]  H. Teraoka,et al.  Degradation of human brain natriuretic peptide (BNP) by contact activation of blood coagulation system. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[79]  D. Barnett,et al.  Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. , 2000, European heart journal.

[80]  K. Kangawa,et al.  Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. , 2000, Circulation.

[81]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[82]  M. Kinoshita,et al.  Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. , 1999, European heart journal.

[83]  Horng H. Chen,et al.  The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. , 1999, Proceedings of the Association of American Physicians.

[84]  H. Teraoka,et al.  Stability of brain natriuretic peptide (BNP) in human blood samples. , 1999, Clinica chimica acta; international journal of clinical chemistry.

[85]  T. Nakayama,et al.  Structure of the type B human natriuretic peptide receptor gene and association of a novel microsatellite polymorphism with essential hypertension. , 1999, Circulation research.

[86]  H. Tunstall-Pedoe,et al.  Biochemical detection of left-ventricular systolic dysfunction , 1998, The Lancet.

[87]  P. Poole‐Wilson,et al.  Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care , 1997, The Lancet.

[88]  A. Gerbes,et al.  Transcription of brain natriuretic peptide and atrial natriuretic peptide genes in human tissues. , 1994, The Journal of clinical endocrinology and metabolism.

[89]  A. Richards,et al.  Plasma brain natriuretic peptide in assessment of acute dyspnoea , 1994, The Lancet.

[90]  J. Lewicki,et al.  Human and canine gene homologs of porcine brain natriuretic peptide. , 1989, Biochemical and biophysical research communications.

[91]  Naoto Minamino,et al.  A new natriuretic peptide in porcine brain , 1988, Nature.

[92]  R. Latini,et al.  An International Consensus Statement Regarding Amino-Terminal Pro-B- Type Natriuretic Peptide Testing: The International NT-proBNP Consensus Panel , 2008 .

[93]  A. Lambeir,et al.  Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. , 2006, Clinical chemistry.

[94]  A. Kastrati,et al.  A prospective cohort study of prognostic power of N-terminal probrain natriuretic peptide in patients with non-ST segment elevation acute coronary syndromes , 2006, Clinical Research in Cardiology.

[95]  D. Staub,et al.  B-type natriuretic peptide for acute dyspnea in patients with kidney disease: insights from a randomized comparison. , 2005, Kidney international.

[96]  A. Lavoinne,et al.  Le BNP : aspects physiologiques, biologiques et cliniques , 2005 .

[97]  O. Pedersen,et al.  Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria , 2004, Diabetologia.